How should extravasation of a vesicant medication be managed?

Management of Vesicant Extravasation

When extravasation of a vesicant medication occurs, immediately stop the infusion, attempt to aspirate residual drug through the existing catheter, remove the catheter, apply the appropriate thermal compress (cold for anthracyclines/vinca alkaloids, warm for most other vesicants), administer specific antidotes when available, and document the injury with photographic evidence. 1

Immediate Actions (Step-by-Step Algorithm)

1. Stop and Aspirate

• Immediately stop the infusion at first suspicion of extravasation
• Do NOT remove the catheter yet
• Attempt to aspirate as much of the extravasated drug as possible through the existing IV access
• Disconnect the infusion tubing but leave the catheter in place temporarily 1

2. Remove Access and Mark the Area

• After aspiration attempts, remove the catheter
• Mark the affected area with a pen to track progression
• Take photographs for documentation 2
• Estimate and document the volume of extravasated drug

3. Apply Thermal Compress (Drug-Specific)

Cold compresses (15-20 minutes, 4 times daily for 24-48 hours):

• Anthracyclines (doxorubicin, daunorubicin, epirubicin)
• Vinca alkaloids (vincristine, vinblastine, vinorelbine)
• Mitomycin C 1, 3

Warm compresses (15-20 minutes, 4 times daily):

• Most other vesicants including taxanes, alkylating agents
• Osmotic vesicants
• pH-related vesicants 3

Critical caveat: Never apply heat to anthracycline or vinca alkaloid extravasations, as this increases tissue damage through enhanced drug penetration.

4. Administer Antidotes (When Available)

The evidence supports specific antidotes for certain vesicants 4, 5:

Dexrazoxane (for anthracycline extravasation):

• Most important antidote with strongest evidence
• Must be given within 6 hours of extravasation
• Dosing: 1000 mg/m² IV on day 1,1000 mg/m² on day 2,500 mg/m² on day 3
• Administered through a different venous access site

Hyaluronidase (for vinca alkaloids, taxanes, and hyperosmolar agents):

• Inject subcutaneously around the extravasation site
• Typical dose: 150-900 units divided into multiple injections in a clockwise pattern around the affected area
• Facilitates drug dispersion and absorption 3, 6

Sodium thiosulfate (for mechlorethamine/nitrogen mustard):

• Mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water
• Inject subcutaneously into the extravasation site

Dimethyl sulfoxide (DMSO) (alternative for anthracyclines where dexrazoxane unavailable):

• Apply topically to affected area
• Less preferred than dexrazoxane

5. Elevate and Monitor

• Elevate the affected extremity above heart level
• Avoid applying pressure to the site
• Monitor for progression: increasing pain, erythema, induration, blistering, or necrosis 1

6. Early Surgical Referral

Immediate surgical consultation indicated for:

• Central venous access device (CVAD) extravasations with large volumes
• Anthracycline extravasations (high risk of tissue necrosis)
• Signs of compartment syndrome
• Progressive tissue injury despite conservative management
• Extravasation near joints or neurovascular structures 4, 5

The ONS/ASCO guideline emphasizes early surgical referral for CVAD extravasations, as these often involve larger volumes and deeper tissue injury 4.

Common Pitfalls to Avoid

Do NOT:

• Apply ice to non-anthracycline/non-vinca alkaloid extravasations
• Apply heat to anthracycline or vinca alkaloid extravasations
• Flush the IV line after suspecting extravasation (this pushes more drug into tissues)
• Delay antidote administration beyond the therapeutic window
• Underestimate the severity based on initial appearance (tissue damage often progresses over 48-96 hours)

Critical timing issue: Dexrazoxane loses effectiveness after 6 hours, and tissue damage from anthracyclines can progress for days even with minimal initial symptoms 4.

Documentation Requirements

Document the following immediately 1, 2:

• Time of extravasation recognition
• Drug name, concentration, and estimated extravasated volume
• Patient symptoms (pain, burning, swelling)
• Physical findings (erythema, induration, blanching)
• Photographs of the site
• Interventions performed and timing
• Follow-up plan

Follow-Up Protocol

• Reassess at 24 hours, 48 hours, and 1 week
• Watch for delayed manifestations: blistering, skin breakdown, ulceration
• Consider wound care specialist involvement if tissue breakdown occurs
• Patient should report immediately: increasing pain, fever, expanding erythema, or drainage 7

The evidence base for extravasation management relies heavily on case series and expert consensus rather than randomized trials, given the relative rarity and ethical constraints of studying these injuries 5. However, the ESMO-EONS guidelines provide the most comprehensive framework, and the recent ONS/ASCO guideline reinforces the importance of antidote use and early surgical consultation for high-risk cases 1, 4.